Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis

Li, Zhongwen; Niu, Sheng; Guo, Baojie; Gao, Tingting; Wang, Lei; Wang, Yukai; Wang, Liu; Tan, Yunfei; Wu, Jun; Hao, Jie

doi:10.1111/cpr.12939

Cited by 82 publications

(75 citation statements)

References 115 publications

(219 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We hypothesize that the anti-inflammatory MSC effect attenuated the recruitment of both macrophages and mononuclear cells to the inflamed lung tissue, further inducing more regulatory dendritic cells; these combined with increased IL-10 and vascular endothelial growth factor might have promoted lung repair. The effect of secreted exosomes has also been documented on antigen presentation functions, differentiation, and maturation of dendritic cells, neutrophils, and other immune cells (for details see recent reviews Abraham and Krasnodembskaya, 2020 ; Li et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

“…The main advantage of the use of MSCs for clinical research lies with their hypoimmunogenicity, and they are thus known as “immune-privileged cells.” They do not express human leukocyte antigen (HLA) class II molecules or costimulatory molecules such as CD40, CD40L, CD80, and CD86 and express low levels of HLA class I molecules. These characteristics permits the MSCs to escape the cytotoxic effects of lymphocytic T cells, B cells, and natural killer cells ( Rasmusson, 2006 ; Stagg, 2007 ; Weiss, 2014 ; Can and Coskun, 2020 ; Li et al, 2020 ). Furthermore, they are able to detect injury signals in their microenvironment and signal regeneration ( Stappenbeck and Miyoshi, 2009 ; Le Blanc and Mougiakakos, 2012 ; Qin and Zhao, 2020 ).…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Is There an Effect of Fetal Mesenchymal Stem Cells in the Mother–Fetus Dyad in COVID-19 Pregnancies and Vertical Transmission?

Samara

Herlenius

2021

Front. Physiol.

View full text Add to dashboard Cite

Because of the polysystemic nature of coronavirus disease 2019 (COVID-19), during the present pandemic, there have been serious concerns regarding pregnancy, vertical transmission, and intrapartum risk. The majority of pregnant patients with COVID-19 infection present with mild or asymptomatic course of the disease. Some cases were hospitalized, and few needed intensive care unit admission, or mechanical ventilation. There have also been scarce case reports where neonates required mechanical ventilation post COVID-19 pregnancies. Without approved therapies other than dexamethasone, advanced mesenchymal cell therapy is one immunomodulatory therapeutic approach that is currently explored and might hold great promise. We suggest that the circulating fetal stem cells might have an immune-protective effect to mothers and contribute to the often mild and even asymptomatic post-COVID-19 pregnancies. Thus, COVID-19 pregnancies come forth as a paradigm to be further and more comprehensively approached, to understand both the mechanism and action of circulating stem cells in immunoprotection and hypoxia in microcirculation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Is There an Effect of Fetal Mesenchymal Stem Cells in the Mother–Fetus Dyad in COVID-19 Pregnancies and Vertical Transmission?

Samara

Herlenius

2021

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…MSCs isolated from adipose tissue, autologous non-hematopoietic peripheral blood stem cells, not specified MSCs and specific T cells are indicated as exosome sources in these studies. More information on these trials is available in recent reviews and on ClinicalTrials.gov (accessed on 30 December 2020) (e.g., [1,72,126]). The small number of studies presently available does not allow identification of the number of inhaled MSCs to achieve optimum effects and of potential differences in the immune response to allogenic MSCs between intravenous and inhalation administration.…”

Section: Methods For Topical Administration To the Lungsmentioning

confidence: 99%

Therapeutic Potential of Mesenchymal Stem Cells and Their Products in Lung Diseases—Intravenous Administration versus Inhalation

Frőhlich

2021

Pharmaceutics

View full text Add to dashboard Cite

The number of publications studying the therapeutic use of stem cells has steadily increased since 2000. Compared to other applications, there has been little interest in the evaluation of mesenchymal stem cells (MSCs) and MSC-derived products (mostly extracellular vesicles) for the treatment of respiratory diseases. Due to the lack of efficient treatments for acute respiratory distress syndrome caused by infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the action of MSCs has also been studied. This review describes mode of action and use of MSCs and MSC-derived products in the treatment of lung diseases including the respective advantages and limitations of the products. Further, issues related to standardized production are addressed. Administration by inhalation of MSCs, compared to intravenous injection, could decrease cell damage by shear stress, eliminate the barrier to reach target cells in the alveoli, prevent thrombus formation in the pulmonary vasculature and retention in filter for extracorporeal membrane oxygenation. There is more feasible to deliver extracellular vesicles than MSCs with inhalers, offering the advantage of non-invasive and repeated administration by the patient. Major obstacles for comparison of results are heterogeneity of the products, differences in the treatment protocols and small study cohorts.

show abstract

“…As we mentioned before, in severe cases, ARDS condition developed after COVID-19 infection. ARDS usually lead to uncontrolled fibrosis [ 119 ]. Macrophage plays a central role in pulmonary fibrosis resolution.…”

Section: Human Amniotic Mesenchymal Stromal Cellsmentioning

confidence: 99%

Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?

et al. 2021

View full text Add to dashboard Cite

A new coronavirus respiratory disease (COVID-19) caused by the SARS-CoV-2 virus, surprised the entire world, producing social, economic, and health problems. The COVID-19 triggers a lung infection with a multiple proinflammatory cytokine storm in severe patients. Without effective and safe treatments, COVID-19 has killed thousands of people, becoming a pandemic. Stem cells have been suggested as a therapy for lung-related diseases. In particular, mesenchymal stem cells (MSCs) have been successfully tested in some clinical trials in patients with COVID-19. The encouraging results positioned MSCs as a possible cell therapy for COVID-19. The amniotic membrane from the human placenta at term is a valuable stem cell source, including human amniotic epithelial cells (hAECs) and human mesenchymal stromal cells (hAMSCs). Interestingly, amnion cells have immunoregulatory, regenerative, and anti-inflammatory properties. Moreover, hAECs and hAMSCs have been used both in preclinical studies and in clinical trials against respiratory diseases. They have reduced the inflammatory response and restored the pulmonary tissue architecture in lung injury in vivo models. Here, we review the existing data about the stem cells use for COVID-19 treatment, including the ongoing clinical trials. We also consider the non-cellular therapies that are being applied. Finally, we discuss the human amniotic membrane cells use in patients who suffer from immune/inflammatory lung diseases and hypothesize their possible use as a successful treatment against COVID-19.

show abstract

Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 82 publications

References 115 publications

Is There an Effect of Fetal Mesenchymal Stem Cells in the Mother–Fetus Dyad in COVID-19 Pregnancies and Vertical Transmission?

Is There an Effect of Fetal Mesenchymal Stem Cells in the Mother–Fetus Dyad in COVID-19 Pregnancies and Vertical Transmission?

Therapeutic Potential of Mesenchymal Stem Cells and Their Products in Lung Diseases—Intravenous Administration versus Inhalation

Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?

Contact Info

Product

Resources

About